Skip to content

Study · Non-randomized trial · n = 8 · 1998

5 results

Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.

Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO

Human reproduction (Oxford, England)1 Oct 1998Cited by 61 (Europe PMC)

PMID9804218 (opens in a new tab)DOI10.1093/humrep/13.10.2706 (opens in a new tab)PepBankPUB-09804218
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with polycystic ovary syndrome, goserelin decreased serum androgen concentrations (P <0.001).

    In plain wordsIn women with polycystic ovary syndrome, serum androgen concentrations decreased during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseSerum androgen concentrations
    Study

    n = 8

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In women treated with goserelin, serum androgen concentrations also decreased (P <0.001), but there was no significant reduction of hirsutism.
    2 context sentences
    Summary · context
    Thirty-two women with polycystic ovary syndrome (PCOS) were allocated to two antiandrogen treatment regimens; 28 women completed the trial.
    Summary · context
    Twenty women were treated with ethinyloestradiol and cyproterone acetate (EO-CA) cyclically for 6 months and eight women were treated with the gonadotrophin releasing hormone (GnRH) analogue, goserelin for 6 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with polycystic ovary syndrome, goserelin did not significantly reduce hirsutism.

    In plain wordsIn women with polycystic ovary syndrome, goserelin did not significantly reduce hirsutism.

    Peptide
    Goserelin
    Outcome
    No significant changeHirsutism
    Study

    n = 8

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In women treated with goserelin, serum androgen concentrations also decreased (P <0.001), but there was no significant reduction of hirsutism.
    2 context sentences
    Summary · context
    Thirty-two women with polycystic ovary syndrome (PCOS) were allocated to two antiandrogen treatment regimens; 28 women completed the trial.
    Summary · context
    Twenty women were treated with ethinyloestradiol and cyproterone acetate (EO-CA) cyclically for 6 months and eight women were treated with the gonadotrophin releasing hormone (GnRH) analogue, goserelin for 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with polycystic ovary syndrome, insulin sensitivity improved during goserelin treatment (P <0.05).

    In plain wordsIn women with polycystic ovary syndrome, insulin sensitivity improved during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseInsulin sensitivity
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    This group, however, showed an improved insulin sensitivity (P <0.05) despite an unchanged body mass index.
    3 context sentences
    Summary · context
    In women treated with goserelin, serum androgen concentrations also decreased (P <0.001), but there was no significant reduction of hirsutism.
    Summary · context
    Thirty-two women with polycystic ovary syndrome (PCOS) were allocated to two antiandrogen treatment regimens; 28 women completed the trial.
    Summary · context
    Twenty women were treated with ethinyloestradiol and cyproterone acetate (EO-CA) cyclically for 6 months and eight women were treated with the gonadotrophin releasing hormone (GnRH) analogue, goserelin for 6 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with polycystic ovary syndrome, body mass index was unchanged during goserelin treatment.

    In plain wordsIn women with polycystic ovary syndrome, body mass index was unchanged during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    No significant changeBody mass index
    Study

    n = 8

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    This group, however, showed an improved insulin sensitivity (P <0.05) despite an unchanged body mass index.
    3 context sentences
    Summary · context
    In women treated with goserelin, serum androgen concentrations also decreased (P <0.001), but there was no significant reduction of hirsutism.
    Summary · context
    Thirty-two women with polycystic ovary syndrome (PCOS) were allocated to two antiandrogen treatment regimens; 28 women completed the trial.
    Summary · context
    Twenty women were treated with ethinyloestradiol and cyproterone acetate (EO-CA) cyclically for 6 months and eight women were treated with the gonadotrophin releasing hormone (GnRH) analogue, goserelin for 6 months.
  5. 05HumanNon-randomized trialSafety outcome

    In women with polycystic ovary syndrome, bone mineral density was unaltered during goserelin treatment, as in the other group.

    In plain wordsIn women with polycystic ovary syndrome, bone mineral density was unaltered during goserelin treatment, as in the other group.

    Peptide
    Goserelin
    Outcome
    No significant changeBone mineral density
    Study

    n = 8

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral density was unaltered in both treatment groups.
    2 context sentences
    Summary · context
    Thirty-two women with polycystic ovary syndrome (PCOS) were allocated to two antiandrogen treatment regimens; 28 women completed the trial.
    Summary · context
    Twenty women were treated with ethinyloestradiol and cyproterone acetate (EO-CA) cyclically for 6 months and eight women were treated with the gonadotrophin releasing hormone (GnRH) analogue, goserelin for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.